US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ARIAD Pharmaceuticals

23.99

0.0000

Volume:- -

Turnover:- -

Market Cap:4.66B

PE:-133.28

High:23.99

Open:23.99

Low:23.99

Close:23.99

52wk High:23.99

52wk Low:23.99

Shares:194.20M

Float Shares:169.70M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1800

ROE:--

ROA:--

PB:-100.52

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ARIA"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","market":"US","secType":"STK","nameCN":"ARIAD Pharmaceuticals","latestPrice":23.99,"timestamp":1764709200000,"preClose":23.99,"halted":0,"volume":0,"delay":0,"floatShares":169700000,"shares":194200862,"eps":-0.18,"marketStatus":"Post-Mkt","change":0,"latestTime":"12-02 17:37:57 EST","open":23.99,"high":23.99,"low":23.99,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.18,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764723600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":23.99,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","floatShares":169700000,"roa":"--","roe":"--","lyrEps":0,"shares":194200862,"dividePrice":0,"high":23.99,"amplitude":0,"preClose":23.99,"low":23.99,"week52Low":23.99,"pbRate":"-100.52","week52High":23.99,"institutionHeld":0.5771,"latestPrice":23.99,"eps":-0.18,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.18,"open":23.99,"prevYearClose":23.99,"prevWeekClose":23.99,"prevMonthClose":23.99,"prevQuarterClose":23.99,"fiveDayClose":23.99,"twentyDayClose":23.99,"sixtyDayClose":23.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARIA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2016-11-07","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1478494800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-07-28","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1469678400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-05-10","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1462852800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-02-23","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1456203600000,"reportTimeType":"pre","actualEps":-0.32},{"market":"US","date":"2015-11-03","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1446526800000,"reportTimeType":"pre","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARIA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARIA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARIA\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588186061","title":"New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF","url":"https://stock-news.laohu8.com/highlight/detail?id=2588186061","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588186061?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:40","pubTimestamp":1764711600,"startTime":"0","endTime":"0","summary":"TOKYO and CAMBRIDGE, Mass., Dec.  02, 2025  (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massa","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/02/3198449/0/en/New-Data-Presented-at-the-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-Conference-2025-Confirms-Pharmacological-Effect-of-LEQEMBI-lecanemab-irmb-on-Neurotoxic-A%CE%B2-Protofibrils-in-CSF.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AD","ARIA","MCI","BK4132","CSF","CAA"],"gpt_icon":0},{"id":"2588727630","title":"ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727630","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727630?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592200,"startTime":"0","endTime":"0","summary":"Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS’ PRECISE-AD trial ProMIS on track to leverage new plasma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196921/0/en/ProMIS-Neurosciences-Announces-New-Peer-Reviewed-Publication-Showing-Plasma-pTau-as-a-Predictive-Early-Endpoint-in-Alzheimer-s-trials-Supporting-its-Ongoing-Phase-1b-PRECISE-AD-tri.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USA","ARIA","BK4170","BK4132","LU1923622291.USD","PD","AD","BK4595","MSA","LU2125909759.SGD","BK4600","LU1169590202.USD","LU0728928796.USD","BK4023","LU2125909916.SGD","LU0053671581.USD","LU1815336091.USD","LU2211815571.USD","LU0757428866.USD","BK4526","BK4143","LU1169589451.USD"],"gpt_icon":1},{"id":"2588223137","title":"ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588223137","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588223137?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590400,"startTime":"0","endTime":"0","summary":"Cambridge, Massachusetts, Dec.  01, 2025  (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s dise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/01/3196854/0/en/ProMIS-Neurosciences-to-Participate-in-the-8th-Annual-Evercore-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USA","LU2125909916.SGD","BK4600","LU0053671581.USD","PK","HCSG","BK4526","ARIA","XBI","LU2211815571.USD","BK4170","LABU","BK4137","BK4588","BK4023","AD","BK4143","BK4581","LU1169590202.USD","XLV","BK4595","LU2125909759.SGD","BK4585","LU1923622291.USD","LU0128526141.USD","BK4132","LU1815336091.USD","BK4181","PD","LU1169589451.USD","MSA","BK4218","LU0029874061.USD","LU0757428866.USD","LU0728928796.USD"],"gpt_icon":1},{"id":"2586478988","title":"Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2586478988","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586478988?lang=en_us&edition=fundamental","pubTime":"2025-11-25 20:30","pubTimestamp":1764073800,"startTime":"0","endTime":"0","summary":"LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194237/0/en/Eisai-Completes-Rolling-Submission-to-US-FDA-for-LEQEMBI-IQLIK-lecanemab-irmb-Supplemental-Biologics-License-Application-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5TLWC47.USD","FAST","IE00BYQQ9H92.USD","BK4588","BK4585","BK4132","IE00BFXG0V08.USD","MCI","CAA","BK4567","AD","ARIA","BK4104"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ARIA\",params:#limit:6,delay:false,,,undefined,":[]}}